Regeneron Pharmaceuticals Inc (REGN)
Market Closed
2 Apr, 20:00
$
625. 60
+8.6
+1.39%
$
98.44B Market Cap
24.52 P/E Ratio
0% Div Yield
898,401 Volume
42.79 Eps
$ 617
Previous Close Day Range
610.1 628
Year Range
610.1 1,211.2
Earnings results expected in 27 days
Summary
REGN closed today higher at $625.6, an increase of 1.39% from yesterday's close, completing a monthly decrease of -10.87% or $76.31. Over the past 12 months, REGN stock lost -13.21%.
REGN is not paying dividends to its shareholders.
The last earnings report, released on Jan 31, 2025, exceeded the consensus estimates by 0.69%. On average, the company has surpassed earnings expectations by 0.8%, based on the last three reports. The next scheduled earnings report is due on Apr 30, 2025.
The stock of the company had never split.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track REGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
REGN Chart
Regeneron Pharmaceuticals Inc Dividends
REGN is not paying dividends to its shareholders.
Regeneron Pharmaceuticals Inc Earnings
| 30 Apr 2025 (27 Days) Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
| 31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
| 1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
| 2 May 2024 Date | | 10.09 Cons. EPS | 9.55 EPS |
REGN is not paying dividends to its shareholders.
| 30 Apr 2025 (27 Days) Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
| 31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
| 1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
| 2 May 2024 Date | | 10.09 Cons. EPS | 9.55 EPS |
Regeneron Pharmaceuticals Inc (REGN) FAQ
What is the stock price today?
The current price is $625.60.
On which exchange is it traded?
Regeneron Pharmaceuticals Inc is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is REGN.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 98.44B.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Apr 30, 2025.
Has Regeneron Pharmaceuticals Inc ever had a stock split?
No, there has never been a stock split.
Regeneron Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Dr. Leonard S. Schleifer M.D., Ph.D. CEO | NASDAQ (NGS) Exchange | US75886F1075 ISIN |
| US Country | 13,450 Employees | - Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Products and Services
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
- EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
- Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
- Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
- REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
- Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
- Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
- ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
- ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.
Contact Information
Address: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Phone: 914 847 7000
Website: https://www.regeneron.com
2025 © Marketlog. All Rights Reserved.
